ERSPC bevindingen (meer)
Van ontwikkeling tot gebruik in de klinische praktijk: ERSPC Prostaatwijzer
Ontwikkeling
Toepassing
Nieuwe functies
Validatie
Gebruik in de klinische praktijk
2010-2011
Guazzoni G , Nava L, Lazzeri M, et al. Prostate-Specific Antigen(PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting. EurUrol (2011) in press.
Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16(12):3232-9
Bangma C H, van Schaik RH, Blijenberg B G, Roobol M J, Lilja H, Stenman Ulf-Hakan. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of prostate cancer. Eur J Cancer: 2010 (46) 3109-3119.
Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, et al. A Risk-Based Strategy Improves Prostate-Specific Antigen-Driven Detection of Prostate Cancer. Eur Urol 2010: 57 (1): 79-85.
Jansen F. H., van Schaik R.H.N., Kurstjens J., Horninger W., Klocker H., Bektic J., Wildhagen M.F., Roobol M.J., Bangma C.H., Georg B. Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection. Euro Urol 2010; 57, 921 – 927.
(meer)
Klik hier om naar de